tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Sami Corwin, 4 are a BUY (100%).
Analyst Sami Corwin, currently employed at WILLIAM BLAIR, carries an average stock price target met ratio of 100% that have a potential upside of 53.27% achieved within 139 days.
Sami Corwin’s has documented 6 price targets and ratings displayed on 3 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on CRSP, Crispr Therapeutics AG at 26-Jun-2025.
Analyst best performing recommendations are on AKUS (AKOUOS).
The best stock recommendation documented was for AKUS (AKOUOS) at 9/29/2022. The price target of $12 was fulfilled within 19 days with a profit of $5.7 (90.48%) receiving and performance score of 47.62.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 28-Apr-2021
$13
$-0.29 (-2.18%)
4 years 13 days ago
(19-Oct-2022)
0/2 (0%)
$-0.25 (-1.89%)
Buy Since 27-Apr-2021
$25
4 years 14 days ago
(18-Oct-2022)
0/1 (0%)
$10.97 (78.19%)
Buy Since 29-Sep-2022
$12
4 years 15 days ago
(18-Oct-2022)
1/1 (100%)
$5.7 (90.48%)
19
Hold Since 30-Mar-2021
$20
$6.71 (50.49%)
$24
5 years 7 months 2 days ago
(30-Mar-2021)
1/2 (50%)
$5.41 (37.08%)
42
What Year was the first public recommendation made by Sami Corwin?
